中国药业2018，Vol.27Issue(4)：77-80,4.DOI:10.3969/j.issn.1006-4931.2018.04.026
恶性肿瘤患者甲氨蝶呤血药浓度监测与安全性Meta分析
Meta-Analysis on Blood Concentration Monitoring on Methotrexate and Its Safety for Malignant Tumor Patients
摘要
Abstract
Objective To evaluate the safety of blood concentration monitoring on methotrexate for malignant tumor patients . Methods Randomized controlled trials(RCTs) and observational studies were searched from PubMed,Cochrane Library,EMBase,Ovid Technologies,CNKI,VIP and Wanfang data. According to the inclusion and exclusion criteria,the qualified literatures were selected and the Meta-analysis was performed. The retrieval time was from the of establishment of databases to the October 2016. The patients with malignant tumor treated with methotrexate and performed quality evaluation of blood concentration were included,including 287 patients and 2 tumor types,the Revman 5. 3 software was used to carry out statistics and analysis for the results. Results Three RCTs and one observational studies were included. Compared with the tumor patients who did not do blood concentration monitoring,the adverse reactions included adverse reactions in gastrointestinal tract,oral ulcer,abnormal liver function,limb discomfort,skin and mucosa damage in the blood concentration monitoring group were significantly reduced(P < 0. 05),but the incidence rate of myelosuppression was high. Conclusion Blood concentration monitoring for malignant tumor patients treated with methotrexate can effectively reduce the in-cidence of adverse reactions.关键词
甲氨蝶呤/血药浓度/恶性肿瘤/Meta分析/药品不良反应Key words
methotrexate/blood concentration/malignant tumor/Meta-analysis/adverse drug reaction分类
医药卫生引用本文复制引用
方琴,马丹,龙如洋,何满菊,代忠建..恶性肿瘤患者甲氨蝶呤血药浓度监测与安全性Meta分析[J].中国药业,2018,27(4):77-80,4.基金项目
贵州省科技计划项目[黔科合SY字[ 2015 ] 3036 ]. （）
